DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/74spvh/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- Seattle Genetics, Inc.
- Celldex Therapeutics, Inc.
- Constellation Pharmaceuticals, Inc.
- Small Molecules to Inhibit BET for Cancer
- Monoclonal Antibody Conjugated to Target CD20 for CLL and Burkitt Lymphoma
For more information visit http://www.researchandmarkets.com/research/74spvh/burkitt_lymphoma